2 results
Approved WMORecruiting
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or without either bevacizumab or cetuximab as first-line (1L) treatment in adults with HER2 positive (HER2+)…
Approved WMORecruiting
The aim of this study is to collect data to confirm clinical safety and performance of the Amvia pacemaker family to fulfil the regulatory requirements for products that are available on the market. The collected data may also be used to support…